Drawing for LCA PHARMACEUTICAL

USPTO serial 79203264

LCA PHARMACEUTICAL

Reviewed by CopyMark Law Group

Reg. 5420383Status 709
Filing date
Status date
Registration date
Mar 13, 2018
Examiner
TWOHIG, SHANNON MARIE
Law office
TMO LAW OFFICE 121

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LCA PHARMACEUTICAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Leigh Ann Lindquist

Leigh Ann Lindquist Sughrue Mion, PLLC2100 Pennsylvania Avenue, N.W.Suite 800Washington, DC 20037

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products, namely, preparations for the treatment of osteoarthritis and other joint diseases; preparations for the treatment of pain and joint diseases, particularly osteoarthritis; injectable preparations for use in rheumatology, presented in the form of pre-filled disposable sterile syringes; preparations for dermatological use for filling in face wrinkles; pharmaceutical preparations for dermatological use; injectable preparations for dermatological use presented in the form of sterile pre-filled disposable syringes; Sterile, isotonic and preservative-free single doses for symptomatic treatments of eye irritations and for nose and eye careSECTION 71 - CANCELLED—
010Surgical and medical apparatus and instruments, namely, sterile single use instrumentation for cataract surgery; Medical devices for intracorporal injection, namely, lenses in the nature of intraocular prostheses for surgical implantation packed in an injector; medical devices for intracorporeal injection; medical devices for intracorporeal injection consisting of a disposable sterile syringe; artificial implants, namely introcular implants; sterile intraocular implants of artificial material and medical devices for use in cataract surgerySECTION 71 - CANCELLED—
042Pharmaceutical research services; medical research services; scientific data analysis services; chemical analyses; chemical research; medical data analysis services; scientific research services for medical purposes, particularly design and development of implantable medical devices for use in ophthalmology, rheumatology and dermatologySECTION 71 - CANCELLED—
044Medical services; medical assistance; health counseling services; pharmacy advice, namely, medical advice related to pharmaceuticals; health care for human beings; advisory services and medical services in the field of rheumatology and dermatology; hygiene and beauty care; all the aforementioned services not in the field of ophthalmologySECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 12, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 24, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Oct 2, 2025XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Oct 2, 2025XXCRGENERIC MADRID TRANSACTION CREATED—
May 27, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 27, 2024C71TCANCELLED SECTION 71—
Mar 13, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Aug 24, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 20, 2018XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jun 20, 2018XXCRGENERIC MADRID TRANSACTION CREATED—
Jun 13, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 13, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 26, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 26, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 22, 2017GPNXNOTIFICATION PROCESSED BY IB—
Dec 6, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 6, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 6, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Nov 14, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 14, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Nov 14, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 14, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 14, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 21, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 21, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 21, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 20, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 20, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 9, 2017RFNTREFUSAL PROCESSED BY IB—
Mar 21, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 21, 2017RFRRREFUSAL PROCESSED BY MPU—
Mar 21, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 21, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 20, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 17, 2017DOCKASSIGNED TO EXAMINER—
Mar 17, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 16, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance